Education Library

Resources for Health Care Professionals

Filter Results





April 15, 2021

First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella® Heart Pumps

The PROTECT IV RCT will leverage advancements in technology and best practices learned since the completion of the PROTECT II RCT and the FDA pre-market approval for Impella 2.5® for high-risk PCI. 

March 1, 2021

Italian Paper Evaluates Completeness of Revascularization in Complex CAD

Sergio Leonardi, MD, and Stefano De Servi, MD, discuss their paper evaluating completeness of revascularization in patients with complex, stable CAD who underwent PCI.

February 23, 2021

Impact of Impella® on Dissected Coronary Artery Hemodynamics

Kiyotake Ishikawa, MD, discusses his paper on the impact of Impella on dissected coronary artery hemodynamics in a porcine model.

November 5, 2020

Abstract Presentation Examining the Influence of Analytic Methodology on Clinical Outcomes

Jeffrey Moses, MD, presents an abstract investigating  the limitations of administrative databases and the potential to generate misleading or inconsistent conclusions. 

October 27, 2020

Intermediate-Term Left Ventricular Function Following Non-Emergent Impella Protected PCI: Restore EF Study

Mitul Patel, MD, shares intermediate-term results from RESTORE EF, a multicenter, prospective, observational, single-arm study that is still actively enrolling patients

October 27, 2020

Results From PROTECT III, the Largest Prospective Multi-Center Single-Arm Study

Jeffrey Moses, MD, presents results from PROTECT III, the largest prospective study of Impella for high-risk PCI in the real world.

October 6, 2020

Your Destination for TCT 2020 Event Resources

TCT Connect highlighted the benefits of a more complete revascularization with Impella® heart pumps in high-risk PCI patients and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients.

August 27, 2020

The Impact of Extensive Revascularization in Protected PCI and Impella® Support in Cardiogenic Shock

Armin Klesius, MD, discusses R-IMP-IT results and the importance of this data in clinical practice with Cristina Aurigemma MD, Professor Francesco Burzotta, MD, and Professor Carlo Trani, MD.

August 25, 2020

What is the PROTECT Series?

This FAQ discusses the PROTECT series of FDA clinical studies, which include the PROTECT I study, the PROTECT II randomized controlled trial, and the PROTECT III study. 

May 29, 2020

No Increase in Mortality in Impella®-Supported Nonemergent High-Risk PCI

No increase in mortality seen in patients undergoing nonemergent high-risk Protected PCI in recent paper by Samin Sharma, MD, and colleagues.

May 8, 2020

Activating Cath Labs for Emergent Procedures Amid COVID-19: Best Practices for STEMI and RV Dysfunction

As emergent cath lab procedures resume amid COVID-19, Ehtisham Mahmud, MD, shares best practices for STEMI and William O’Neill, MD, discusses right ventricular dysfunction.

February 24, 2020

Amin et al. 

The objective of the analysis, as stated in Amin et al., was “to describe the trends in Impella® use; variation in Impella use and its outcomes over 13 years.

February 3, 2020

Bleeding and Vascular Complications: A Look at Impella® Data Over Time

Daniel Raess, MD, describes how Impella® bleeding and vascular complication data has evolved over time and how it compares to data for other forms of mechanical circulatory support.

January 6, 2020

Discover New Data on Protected PCI versus Bailout PCI

Alexander Truesdell, MD, discusses Protected PCI versus bailout PCI using data from the cVAD Study and the PROTECT III study. 

November 26, 2019

PROTECT Series of Clinical Studies Provides Mounting Evidence for Impella® Support in High-risk PCI

Impella “reduced major adverse events, critical care and readmission length of stay, and readmission cost over the 90-day EOC (episode of care), and was determined to be cost-effective over the long-term.”